Highlight
- High treatment complexity in major depressive disorder (MDD) is significantly associated with 37 phenotypic traits, including suicidal ideation, chronic pain, and atypical depression subtypes.
- Polygenic scores (PGS) for MDD, ADHD, bipolar disorder, and neuroticism correlate with the number of different antidepressant classes required by patients.
- The study identified a novel genetic locus, SLAMF3/LY9, where the rs4656934 variant is associated with reduced odds of sustained SSRI use, suggesting an immune-related component to treatment response.
- Sustained-use patterns for specific antidepressants are linked to distinct clinical profiles, such as variations in body mass index (BMI) and co-occurring psychiatric conditions.
Introduction: The Challenge of Precision Prescribing in MDD
Major depressive disorder (MDD) remains a leading cause of disability worldwide, yet the pharmacological management of the condition is frequently characterized by a frustrating cycle of trial and error. Current clinical guidelines generally recommend selective serotonin reuptake inhibitors (SSRIs) as first-line therapy. However, approximately one-third of patients fail to achieve remission with their initial prescription. This lack of precision not only delays recovery but also increases the burden of side effects and healthcare costs.
The quest for biomarkers that can predict which patient will respond to which medication—the essence of precision psychiatry—has historically focused on clinical symptoms. However, recent advancements in genomics and large-scale data analytics have allowed researchers to look deeper into the biological and polygenic underpinnings of treatment response. A landmark study published in JAMA Psychiatry by Walker et al. (2026) provides a comprehensive analysis of how genetics and phenotypic traits influence antidepressant prescription patterns and treatment complexity over time.
Study Design and Methodology
This retrospective cohort study utilized data from the Australian Genetics of Depression Study (2017-2018). The researchers analyzed 12,074 adult participants (mean age approximately 43 years; 75% female) who had a lifetime diagnosis of MDD and had filled at least one prescription for the ten most common antidepressants between 2013 and 2017. Of this group, 8,898 participants provided genotyping data for genomic analysis.
The study focused on two primary metrics of treatment response:
1. Treatment Complexity
This was defined by the number of different antidepressant classes (e.g., SSRIs, SNRIs, TCAs) a patient was prescribed over the 4.5-year study period. Higher complexity often serves as a proxy for difficult-to-treat or treatment-resistant depression.
2. Sustained Use
Participants were categorized into ‘sustained-use 360’ groups if they filled a single antidepressant for 360 or more cumulative days within the 4.5-year window. This metric aimed to identify patients who achieved a stable treatment regimen.
The researchers integrated self-reported phenotypes (44 traits) and polygenic scores (PGS) for 15 psychiatric and personality traits to identify associations with these medication patterns. Furthermore, genome-wide association studies (GWAS) were conducted to pinpoint specific genetic loci associated with sustained SSRI or SNRI use.
Phenotypic and Genetic Drivers of Treatment Complexity
The results revealed a stark correlation between clinical complexity and patient phenotypes. High treatment complexity (switching between multiple classes of antidepressants) was significantly associated with 37 out of 44 self-reported traits. Patients requiring more complex regimens were more likely to report recurrent MDD, suicidal ideation, smoking, chronic pain, and sleep disturbances. Furthermore, specific depression subtypes—notably circadian and atypical depression—were strongly linked to increased medication switching.
From a genetic perspective, the study found that polygenic risk for several psychiatric conditions tracked with treatment complexity. Higher polygenic scores for MDD (β, 0.04; P = 1.2 × 10⁻⁸), ADHD (β, 0.03; P = 2.1 × 10⁻⁵), bipolar disorder (β, 0.03; P = 1.2 × 10⁻⁴), and neuroticism (β, 0.02; P = 1.3 × 10⁻³) were all associated with a higher number of antidepressant classes. This suggests that the genetic burden of psychiatric vulnerability contributes directly to how difficult a patient’s depression is to manage pharmacologically.
Profiles of Sustained Antidepressant Use
Approximately 61% of the cohort met the criteria for a sustained-use 360 group. Interestingly, these groups were not uniform; different medications were associated with distinct patient profiles. For example, sustained use of certain antidepressants showed specific associations with body mass index (BMI) and the presence of co-occurring conditions. This suggests that clinicians may already be implicitly ‘matching’ patients to drugs based on side-effect profiles (e.g., avoiding weight-gain-prone drugs in patients with high BMI), or that certain biological subtypes of MDD are more responsive to specific mechanisms of action.
While polygenic scores were highly predictive of treatment complexity, they showed surprisingly little association with the sustained-use 360 groups. This indicates that while genetics can help predict who might have a ‘difficult’ clinical course, they are currently less effective at predicting which specific medication will eventually stick.
Genetic Insights: The Role of SLAMF3/LY9
One of the most significant findings of the study was the identification of a novel genetic locus associated with SSRI response. The GWAS identified the immune-related gene SLAMF3/LY9 on chromosome 1. Specifically, the single-nucleotide variant rs4656934 was associated with reduced odds of sustained SSRI use (G allele; OR, 0.81; 95% CI, 0.75-0.87; P = 3.5 × 10⁻⁸).
This finding is particularly intriguing given the growing body of evidence regarding the ‘inflammatory hypothesis’ of depression. SLAMF3 (Signaling Lymphocytic Activation Molecule Family Member 3) and LY9 are involved in immune cell signaling and T-cell activation. The association of an immune-related locus with reduced SSRI persistence suggests that patients with certain inflammatory genetic profiles may be less responsive to standard serotonergic treatments, potentially requiring alternative strategies such as anti-inflammatory adjuncts or non-monotherapy approaches.
Expert Commentary
The findings by Walker et al. represent a significant step forward in understanding the heterogeneity of MDD treatment. By using prescription data as a longitudinal objective marker, the study bypasses some of the recall biases inherent in clinical trials. The strong association between treatment complexity and PGS for ADHD and Bipolar disorder is particularly noteworthy; it suggests that ‘treatment resistance’ in MDD may often be a signal of underlying neurobiological commonalities with other psychiatric domains that are not being addressed by standard antidepressants.
However, limitations must be considered. The study relies on retrospective prescription data, which indicates that a script was filled but does not confirm adherence or actual symptom remission. Furthermore, the cohort was predominantly of European ancestry, which may limit the generalizability of the genetic findings to more diverse populations. The identified locus, SLAMF3/LY9, while statistically significant, requires functional validation in prospective clinical trials to determine its utility as a point-of-care biomarker.
Conclusion and Clinical Implications
This research underscores that antidepressant response is a complex interplay of clinical phenotypes and polygenic risk. For the clinician, the study highlights that patients with high neuroticism, comorbid ADHD traits, or atypical depression subtypes are at a higher risk for a ‘trial-and-error’ trajectory and may benefit from earlier intensive intervention or multi-modal therapy.
The discovery of the SLAMF3/LY9 locus opens new avenues for exploring the role of the immune system in antidepressant efficacy. As we move toward an era of precision psychiatry, integrating polygenic risk scores and specific genetic markers into clinical decision-making holds the potential to reduce the time to remission and improve the quality of life for millions of patients living with MDD.
References
1. Walker A, Mitchell BL, Lin T, et al. Genetic and Phenotypic Associations With Sustained Antidepressant Use in Major Depressive Disorder. JAMA Psychiatry. 2026; doi:10.1001/jamapsychiatry.2025.4372.
2. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-1366.
3. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk loci and refine the genetic architecture of major depression. Nature Genetics. 2018;50(5):668-681.
